According to data referred to by Barr, the drug had annual sales of approximately $346 million for the twelve months ended March 2006.
Nasacort AQ (triamcinolone acetonide) nasal spray is specifically indicated for the treatment of the nasal symptoms of seasonal and perennial allergic rhinitis in adults and children 6 years of age and older.
Barr developed its generic version of the product with Perrigo Company and the companies will share in the costs and potential benefits relating to the product.
After being informed of the patent challenge, Aventis filed a suit in the US District Court of Delaware to prevent Barr from proceeding with the commercialization of its product.